Belite Bio, Inc. (D01)
XFRA 
Summary
D01 Chart
Belite Bio's drug for genetic eye disease meets main goal in late-stage trial
Belite Bio said on Monday that its experimental drug for a rare genetic eye disease met the main goal in a late-stage study.
Belite Bio, Inc (BLTE) Q3 2025 Earnings Call Transcript
Belite Bio, Inc ( BLTE ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Julie Fallon Yu-Hsin Lin - Chairman of the Board of Directors & CEO Hao-Yuan Chuang - CFO & Director Nathan L. Mata - Chief Scientific Officer Hendrik Scholl - Chief Medical Officer Conference Call Participants Yi Chen - H.C.
Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2025 Earnings Conference Call August 11, 2025 4:30 PM ET Company Participants Hao-Yuan Chuang - CFO & Director Hendrik P.N. Scholl - Chief Medical Officer Nathan L.
Belite Bio, Inc. (D01) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Belite Bio, Inc. ever had a stock split?
Belite Bio, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Yu-Hsin Lin CEO | XFRA Exchange | US07782B1044 ISIN |
| US Country | 25 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Belite Bio, Inc is a clinical stage biopharmaceutical drug development company focused on addressing the challenges of retinal degenerative eye diseases, which currently have unmet medical needs. Founded in 2016 and headquartered in San Diego, California, the company is a subsidiary of Lin Bioscience International Ltd. Belite Bio, Inc's dedication to innovative research and development has positioned it as a promising entity in the healthcare sector, especially in the realm of eye health.
Products and Services
LBS-008 (Tinlarebant)
This leading product candidate from Belite Bio, Inc is a testament to the company's forward-thinking approach to eye health. Tinlarebant is an orally administered tablet designed to be taken once a day. It aims to maintain the health and integrity of retinal tissues, offering hope to patients suffering from autosomal recessive Stargardt disease and geographic atrophy. These conditions previously had limited treatment options, making Tinlarebant a potentially transformative solution.
LBS-009
Underpinning Belite Bio's diversified research pipeline is LBS-009, an innovative therapeutic option that is currently in the preclinical development phase. This anti-retinol binding protein 4 oral therapy is being explored for its potential applications in treating liver diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and type 2 diabetes. With these conditions affecting a significant portion of the global population, LBS-009 represents a meaningful step toward addressing a critical healthcare challenge.
